2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 747

The Influence of Depression on Clinical Features of Systemic Lupus Erythematosus
Abstract Number: 1369

The Influence of Hand Osteoarthritis on Bone Microstructure and Biomechanical Properties of Radial Bone
Abstract Number: 2517

The JAK1-Selective Inhibitor Filgotinib Reverses the Disease-Associated Transcriptional Profile Found in the Blood of Patients with Active Rheumatoid Arthritis
Abstract Number: 2506

The Joint Disease Burden in Patients with Secondary Sjögren’s Syndrome and RA Compared to Patients with RA Only
Abstract Number: 96

The Liver X Receptor Modulates Inflammatory Cytokines Based on Lxrα Polymorphism in Monocyte-Derived Macrophages and Patients with Systemic Lupus Erythematosus
Abstract Number: 464

The Long Term Outcomes in Chinese Children Diagnosed with Systemic Lupus Erythematosus and Biopsy Proven Lupus Nephritis – a 18-Year Cohort
Abstract Number: 254

The Lumbar Spine Is Straight in Fibromyalgia Patients
Abstract Number: 521

The Lung in an English Cohort of Rheumatoid Arthritis Patients – an Overview of Different Types of Involvement and Treatment
Abstract Number: 1694

The Lupus Severity Index Accurately Identifies Patients with Severe SLE in a Multi-Ethnic Cohort
Abstract Number: 809

The Lymphangiogenetic Factors VEGF-C, CCL21 and Ang-2 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Abstract Number: 708

The Montreal Cognitive Assessment Test. a Useful Tool in Screening of Cognitive Impairment in Patients with Systemic Lupus Erythematosusshort Title: Cognitive Impairment in SLE
Abstract Number: 1500

The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients
Abstract Number: 1929

The Neutrophil-Lymphocyte Ratio in Newly Diagnosed Rheumatoid Arthritis and Its Ability to Predict Treatment Failure
Abstract Number: 2012

The Novel G58V Mutation in the TNFRSF1A Gene Identified in a Family with Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) Decreases the Cell Surface Expression of TNFR1
Abstract Number: 1793

The Omeract Core Domain Set for Clinical Trials in Behçet’s Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].